Developing recombinant and synthetic vaccines for the treatment of melanoma

Nicholas P. Restifo, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

To develop new vaccines for the treatment of patients with cancer, target antigens presented on tumor cell surfaces have been cloned. Many of these antigens are non-mutated differentiation antigens and are expressed by virtually all melanomas, making them attractive components for a widely efficacious melanoma vaccine. These antigens are also expressed by melanocytes, however, and are likely to be subject to immune tolerance. A central challenge for tumor immunologists has thus been the breaking of tolerance to cancer antigens. We review recent clinical trials using experimental cancer vaccines, including recent evidence that therapeutic vaccines can induce objective responses in patients with metastatic malignant melanoma. We focus on the foundations of these approaches in new experimental animal models designed to test novel vaccines and report on what these new models predict for the future development of therapeutic vaccines for cancer.

Original languageEnglish (US)
Pages (from-to)50-57
Number of pages8
JournalCurrent Opinion in Oncology
Volume11
Issue number1
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Synthetic Vaccines
Melanoma
Vaccines
Antigens
Cancer Vaccines
Neoplasms
Immune Tolerance
Melanocytes
Differentiation Antigens
Therapeutics
Animal Models
Clinical Trials

ASJC Scopus subject areas

  • Cancer Research

Cite this

Developing recombinant and synthetic vaccines for the treatment of melanoma. / Restifo, Nicholas P.; Rosenberg, Steven A.

In: Current Opinion in Oncology, Vol. 11, No. 1, 1999, p. 50-57.

Research output: Contribution to journalArticle

Restifo, Nicholas P. ; Rosenberg, Steven A. / Developing recombinant and synthetic vaccines for the treatment of melanoma. In: Current Opinion in Oncology. 1999 ; Vol. 11, No. 1. pp. 50-57.
@article{eace424eefc54d8393c5dd26b31cfd1f,
title = "Developing recombinant and synthetic vaccines for the treatment of melanoma",
abstract = "To develop new vaccines for the treatment of patients with cancer, target antigens presented on tumor cell surfaces have been cloned. Many of these antigens are non-mutated differentiation antigens and are expressed by virtually all melanomas, making them attractive components for a widely efficacious melanoma vaccine. These antigens are also expressed by melanocytes, however, and are likely to be subject to immune tolerance. A central challenge for tumor immunologists has thus been the breaking of tolerance to cancer antigens. We review recent clinical trials using experimental cancer vaccines, including recent evidence that therapeutic vaccines can induce objective responses in patients with metastatic malignant melanoma. We focus on the foundations of these approaches in new experimental animal models designed to test novel vaccines and report on what these new models predict for the future development of therapeutic vaccines for cancer.",
author = "Restifo, {Nicholas P.} and Rosenberg, {Steven A.}",
year = "1999",
doi = "10.1097/00001622-199901000-00012",
language = "English (US)",
volume = "11",
pages = "50--57",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Developing recombinant and synthetic vaccines for the treatment of melanoma

AU - Restifo, Nicholas P.

AU - Rosenberg, Steven A.

PY - 1999

Y1 - 1999

N2 - To develop new vaccines for the treatment of patients with cancer, target antigens presented on tumor cell surfaces have been cloned. Many of these antigens are non-mutated differentiation antigens and are expressed by virtually all melanomas, making them attractive components for a widely efficacious melanoma vaccine. These antigens are also expressed by melanocytes, however, and are likely to be subject to immune tolerance. A central challenge for tumor immunologists has thus been the breaking of tolerance to cancer antigens. We review recent clinical trials using experimental cancer vaccines, including recent evidence that therapeutic vaccines can induce objective responses in patients with metastatic malignant melanoma. We focus on the foundations of these approaches in new experimental animal models designed to test novel vaccines and report on what these new models predict for the future development of therapeutic vaccines for cancer.

AB - To develop new vaccines for the treatment of patients with cancer, target antigens presented on tumor cell surfaces have been cloned. Many of these antigens are non-mutated differentiation antigens and are expressed by virtually all melanomas, making them attractive components for a widely efficacious melanoma vaccine. These antigens are also expressed by melanocytes, however, and are likely to be subject to immune tolerance. A central challenge for tumor immunologists has thus been the breaking of tolerance to cancer antigens. We review recent clinical trials using experimental cancer vaccines, including recent evidence that therapeutic vaccines can induce objective responses in patients with metastatic malignant melanoma. We focus on the foundations of these approaches in new experimental animal models designed to test novel vaccines and report on what these new models predict for the future development of therapeutic vaccines for cancer.

UR - http://www.scopus.com/inward/record.url?scp=0033002264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033002264&partnerID=8YFLogxK

U2 - 10.1097/00001622-199901000-00012

DO - 10.1097/00001622-199901000-00012

M3 - Article

C2 - 9914879

AN - SCOPUS:0033002264

VL - 11

SP - 50

EP - 57

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 1

ER -